Recombinant modified vaccinia virus Ankara (MVA) multivalent filovirus immunogenic compositions and methods of use

Patent metadata

Field	Value
Publication number	US-10576141-B2
Application number	US-201515508851-A
Country	US
Kind code	B2
Filing date	Sep 3, 2015
Priority date	Sep 3, 2014
Publication date	Mar 3, 2020
Grant date	Mar 3, 2020

Abstract

The present invention relates to an improved filovirus vaccine comprising a recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against filovirus infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) MVA and FPV vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a Marburg virus (MARV) or Ebola virus glycoprotein. Specifically, the invention relates to recombinant MVA comprising Ebola virus glycoprotein and virion protein 40. The invention also relates to products, methods and uses thereof as well as prime/boost regimens of MVA and genetically engineered (recombinant) FPV, e.g., suitable to induce a protective immune response in a subject.

First claim

The invention claimed is:

1. A method of inducing an immune response in a subject comprising administering to a subject a recombinant MVA vector, the recombinant MVA vector comprising a first nucleic acid encoding at least one immunogenic protein of a MARV envelope glycoprotein (GP); a second nucleic acid encoding an immunogenic protein of Zaire Ebola virus (ZEBOV) envelope glycoprotein; a third nucleic acid encoding an immunogenic protein of Sudan Ebola virus (SEBOV) envelope glycoprotein; and a fourth nucleic acid encoding an immunogenic protein of Ebola virus Ivory Coast nucleoprotein.

2. The method of claim 1 , wherein the MARV envelope glycoprotein is full-length MARV-Musoke envelope glycoprotein.

3. The method of claim 2 , wherein the first nucleic acid encodes an immunogenic protein comprising the sequence set forth in SEQ ID NO:6.

4. The method of claim 3 , wherein the first nucleic acid comprises the sequence set forth in SEQ ID NO:5.

5. The method of claim 1 , wherein the recombinant MVA vector comprises a nucleic acid encoding an immunogenic protein having a sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:20, SEQ ID NO:29, SEQ ID NO:31, and SEQ ID NO:37.

6. The method of claim 1 , wherein the recombinant MVA vector comprises a nucleic acid encoding an immunogenic protein comprising the sequence set forth in SEQ ID NO:6, SEQ ID NO:20, SEQ ID NO:29, or SEQ ID NO:31.

7. The method of claim 6 , wherein said nucleic acid comprises the sequence set forth in SEQ ID NO:5, SEQ ID NO:19, SEQ ID NO:28, or SEQ ID NO:30.

8. The method of claim 1 , wherein the administration provides protective immunity or a protective immune response in the subject.

9. The method of claim 1 , wherein the recombinant MVA vector comprises at least one nucleic acid encoding the sequences set forth in SEQ ID NO:6, SEQ ID NO:20, SEQ ID NO:29, and SEQ ID NO:31.

10. The method of claim 1 , wherein the recombinant MVA further comprises a nucleic acid encoding CD40L.

11. The method of claim 10 , wherein the CD40L comprises the amino acid sequence set forth in SEQ ID NO:10.

12. The method of claim 11 , wherein the nucleic acid encoding CD40L comprises the sequence set forth in SEQ ID NO:9.

Assignees

• Bavarian Nordic As

Inventors

• Volkmann Ariane
• Steigerwald Robin
• Hochrein Hubertus
• Dirmeier Ulrike
• Lauterbach Henning
• Hausmann Jürgen Hausmann

Classifications

• A61P31/14

  for RNA viruses · CPC title

• A61P31/12

  Antivirals · CPC title

• C12N2710/24143

  viral genome or elements thereof as genetic vector · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title

• A61K39/12 Primary

  Viral antigens · CPC title